Articles

An in vitro study to determine whether inactivation of the Notch and wnt-beta-catenin pathways is crucial for cancer stem-cell development and if such a therapeutic approach with a γ-secretase inhibitor would be effective in treating patients with gastric cancer. Read More ›

BBI608/FOLFIRI ± Bevacizumab in Advanced Colorectal Cancer

ASCO 2016 – GI

Initial results from a phase 2 open-label study of NEO-102, a novel chimeric monoclonal antibody targeting a variant of MUC5AC, in patients with chemotherapy-refractory metastatic colorectal cancer. Read More ›

STEAM—Sequential versus Concurrent FOLFOXIRI/Bevacizumab in Metastatic Colorectal Cancer

ASCO 2016 – GI

Results from the phase 1b JAVELIN study of the anti–PD-L1 monoclonal antibody avelumab in patients with advanced gastric or gastroesophageal junction cancer, stratified based on the level of PD-L1 expression. Read More ›

Nivolumab Monotherapy in Advanced Gastroesophageal or Gastric Cancer

ASCO 2016 – GI

Results of an open-label phase 1/2 study evaluating the safety and efficacy of nivolumab monotherapy for patients with advanced gastroesophageal or gastric cancer. Read More ›

Pembrolizumab in PD-L1+ Advanced Esophageal Carcinoma

ASCO 2016 – GI

Results of the phase 1b KEYNOTE-028 study of pembrolizumab in PD-L1+ advanced esophageal carcinoma. Read More ›

The Role of the mTOR Pathway in Cancer Stem Cells in Esophageal Cancer

ASCO 2016 – GI

Investigation of the role of the mTOR pathway on the stemness of a putative cancer stem- cell population in esophageal cancer. Read More ›

Articles

Page 118 of 143